Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Review, Stamelou et al. present an overview of the latest research in 4-repeat tauopathies, with a focus on progressive supranuclear palsy, and discuss how current evidence dictates ongoing and future research goals.
The burden of epilepsy among forcibly displaced persons is thought to be high, and access to treatment is limited. In June 2021, the WHO Secretariat published a draft intersectoral action plan aimed at redressing the global epilepsy treatment gap, providing a valuable opportunity to improve epilepsy treatment for forcibly displaced persons.
The maternal immune activation (MIA) hypothesis proposes that inflammatory perturbations in utero can affect fetal neurodevelopment. This Review examines the emerging human evidence for an association between MIA and childhood neurodevelopmental disorders, including autism spectrum disorder, attention-deficit/hyperactivity disorder and Tourette syndrome.
During Parkinson disease progression, the accumulation of α-synuclein pathology is paralleled by changes in structural and functional connectivity in the brain. Two new studies pinpoint specific alterations in the brain connectome in the early stages of Parkinson disease and suggest future avenues of research to develop connectome-based biomarkers.
Headaches and epilepsy frequently co-exist in the same individual, but the pathophysiological mechanisms underlying this relationship are not yet clear. Here, the authors discuss the epidemiological and pathophysiological links between epilepsy and headache, and apply this knowledge to the clinical management of the two disorders.
In this Review, the authors discuss the alterations to structural and functional brain networks that occur in Alzheimer disease, with a particular focus on the influence of amyloid and tau pathology and genetic factors.
The FDA has granted accelerated approval to aducanumab (Aduhelm) for the treatment of Alzheimer disease with an overly broad label. The decision disregarded key aspects of scientific process and risks eroding public trust in research, regulatory science and the FDA.
The AT(N) system is a classification scheme based on biomarkers that reflect the core pathophysiological features of Alzheimer disease. This Perspective outlines the conceptual framework and clinical importance of the AT(N) system and considers its potential expansion to incorporate biomarkers for additional pathophysiological mechanisms.
Results of a new study have identified an association between risk of incident Parkinson disease and exposure to NO2, which is released into the atmosphere as a result of burning fuels. Parkinson disease has a long prodromal phase, so these findings suggest an opportunity to apply early prevention strategies.